Exclusive: Basilea Pharma set for European roll out of isavuconazole in 2016

19 October 2015

Basilea Pharmaceutica (SIX: BSLN) plans to start selling isavuconazole in Europe next year at a price modestly higher than the current market leader voriconazole, chief commercial officer David Veitch told The Pharma Letter in an interview.

“We are looking to roll out isavuconazole in Europe next year starting with the UK, Germany and Italy and going on to France and Spain later in the year,” David Veitch, chief commercial officer of Basilea told The Pharma Letter in an interview.

Cresemba (isavuconazole) was approved by the US Food and Drug Administration in March this year to treat invasive aspergillosis and invasive mucormycosis for patients 18 years and above. In addition, it has EU and US orphan drug status for the treatment of invasive aspergillosis and mucormycosis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK